At Three Months Post Launch, Two-Thirds of Surveyed U.S. Rheumatologists Believe that Initiations of Pfizer's Xeljanz in the

   At Three Months Post Launch, Two-Thirds of Surveyed U.S. Rheumatologists
   Believe that Initiations of Pfizer's Xeljanz in the Rheumatoid Arthritis
   Treatment Algorithm Will Occur Following at Least Two Biologic Failures

Surveyed US Rheumatologists Believe Actemra is Most at Risk for Displacement
by Xeljanz, According to a New Report from BioTrends Research Group

PR Newswire

EXTON, Pa., April 24 2013

EXTON, Pa., April 24 2013 /PRNewswire/ -- BioTrends Research Group, one of the
world's leading research and advisory firms for specialized biopharmaceutical
issues, finds that two-thirds of surveyed U.S. rheumatologists believe that—at
three months post launch—initiations of Pfizer's Xeljanz in the rheumatoid
arthritis (RA) treatment algorithm will follow methotrexate
failure/intolerance and at least two biologic failures. Only one in ten
surveyed physicians currently plan to use the treatment prior to biologic

(Logo: )

According to the BioTrends Research Group report entitled LaunchTrends^®:
Xeljanz, Wave 2,  surveyed rheumatologists report that among their patients
currently treated with Xeljanz, 87 percent were switched from a biologic
agent, while the remaining 13 percent of current Xeljanz patients were
biologic naive prior to initiation. When questioned directly about agents at
risk for displacement, nearly one-quarter of rheumatologists believe that
Xeljanz is most likely to displace Genentech's Actemra with regard to RA
patient share.

The recently published report also reveals that at three months post launch,
approximately one-third of surveyed rheumatologists report prescribing Xeljanz
in an average of three RA patients. Although rheumatologists anticipate
Xeljanz trial rates to increase in the future, four percent claim that they
will never use Xeljanz, primarily due to efficacy concerns and side effects.

"The percent of rheumatologists who have used Xeljanz in at least one patient
has remained around one-third since the first wave of research, at one-month
post launch," said BioTrends Research Group Associate Director of Immunology
Lynn Price. "However, according to the data, Xeljanz trial rates are
anticipated to double in the coming months."

LaunchTrends^®: Xeljanz, Wave 2  is a four-wave syndicated report series
designed to track the uptake of Xeljanz at one month, three months, six months
and one year following its commercial availability based upon primary research
with U.S. rheumatologists. LaunchTrends assess trial and use of new products,
obstacles to use, reasons to use, typical patient types, line of therapy,
product perceptions, promotional efforts/messages and product satisfaction. In
the current wave of research, BioTrends surveyed 74 U.S. rheumatologists in
February 2013 and conducted qualitative interviews with a subset of 15 of the
respondents in March 2013.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market
research to pharmaceutical manufacturers competing in clinically evolving,
specialty pharmaceutical markets. For information on BioTrends publications
and research capabilities, please contact us at BioTrends
is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources Group

All company, brand, or product names contained in this document may be
trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort

SOURCE BioTrends Research Group

Press spacebar to pause and continue. Press esc to stop.